Research Analysts Offer Predictions for OCUL FY2026 Earnings

Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) – Equities researchers at HC Wainwright reduced their FY2026 earnings estimates for Ocular Therapeutix in a research report issued on Tuesday, November 10th. HC Wainwright analyst Y. Chen now expects that the biopharmaceutical company will post earnings of ($1.62) per share for the year, down from their prior estimate of ($1.49). HC Wainwright has a “Buy” rating and a $28.00 price objective on the stock. The consensus estimate for Ocular Therapeutix’s current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Ocular Therapeutix’s Q4 2026 earnings at ($0.46) EPS, Q1 2027 earnings at ($0.47) EPS, Q2 2027 earnings at ($0.47) EPS, Q3 2027 earnings at ($0.47) EPS, Q4 2027 earnings at ($0.46) EPS and FY2027 earnings at ($1.87) EPS.

Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.06). Ocular Therapeutix had a negative net margin of 648.64% and a negative return on equity of 59.95%. The business had revenue of $12.87 million during the quarter, compared to analyst estimates of $14.27 million. During the same period in the previous year, the business posted ($0.38) earnings per share. The firm’s revenue for the quarter was down 11.5% on a year-over-year basis.

OCUL has been the topic of several other reports. Chardan Capital reiterated a “buy” rating and issued a $23.00 price objective on shares of Ocular Therapeutix in a report on Friday, October 2nd. Royal Bank Of Canada restated an “outperform” rating on shares of Ocular Therapeutix in a research report on Tuesday, September 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ocular Therapeutix in a research note on Thursday, October 15th. Zacks Research raised Ocular Therapeutix from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Finally, UBS Group initiated coverage on Ocular Therapeutix in a research report on Sunday, October 11th. They set a “buy” rating and a $14.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $23.83.

Check Out Our Latest Stock Report on Ocular Therapeutix

Ocular Therapeutix Trading Down 1.1%

Shares of NASDAQ OCUL opened at $6.21 on Thursday. The firm has a fifty day moving average of $7.99 and a 200 day moving average of $8.91. The company has a debt-to-equity ratio of 0.17, a current ratio of 9.12 and a quick ratio of 13.03. Ocular Therapeutix has a one year low of $5.99 and a one year high of $16.44.

Institutional Investors Weigh In On Ocular Therapeutix

Institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. acquired a new stake in shares of Ocular Therapeutix in the second quarter valued at $190,278,000. Octagon Capital Advisors LP grew its stake in Ocular Therapeutix by 20.7% during the 1st quarter. Octagon Capital Advisors LP now owns 3,166,600 shares of the biopharmaceutical company’s stock worth $26,821,000 after purchasing an additional 543,000 shares in the last quarter. Marshall Wace LLP grew its stake in Ocular Therapeutix by 2,047.2% during the 3rd quarter. Marshall Wace LLP now owns 2,706,184 shares of the biopharmaceutical company’s stock worth $20,756,000 after purchasing an additional 2,580,151 shares in the last quarter. Deltec Asset Management LLC grew its stake in Ocular Therapeutix by 6.0% during the 3rd quarter. Deltec Asset Management LLC now owns 2,623,597 shares of the biopharmaceutical company’s stock worth $20,123,000 after purchasing an additional 147,400 shares in the last quarter. Finally, Commodore Capital LP purchased a new stake in Ocular Therapeutix during the 1st quarter worth about $21,810,000. Hedge funds and other institutional investors own 59.21% of the company’s stock.

Insider Buying and Selling

In other news, insider Peter Kaiser sold 9,990 shares of the company’s stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $7.05, for a total value of $70,429.50. Following the transaction, the insider owned 254,388 shares of the company’s stock, valued at $1,793,435.40. This represents a 3.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Pravin Dugel sold 21,649 shares of the stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $10.77, for a total transaction of $233,159.73. Following the transaction, the insider directly owned 2,525,429 shares of the company’s stock, valued at approximately $27,198,870.33. This trade represents a 0.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 98,090 shares of company stock worth $787,920 over the last ninety days. 3.10% of the stock is currently owned by insiders.

More Ocular Therapeutix News

Investors following OCUL have been watching these news items:

Ocular Therapeutix Company Profile

(Get Free Report)

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for eye diseases and conditions. Based in Bedford, Massachusetts, the company uses its proprietary hydrogel-based technology to deliver medicines to the eye over time. Its marketed product, DEXTENZA, is a corticosteroid insert placed in the tear duct by an eye-care professional to treat inflammation and pain following ophthalmic surgery. Ocular Therapeutix also develops investigational therapies for retinal diseases and other eye conditions, including treatments designed for sustained drug delivery.

Read More

Earnings History and Estimates for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.